ORIL is an Australian public, unlisted company with over 500 shareholders and approximately 38 million shares on issue. Maintained by “pre-money” at ~$AUD18 million, cash reserves and eligibility for the government R&D tax rebate, the company is seeking an additional investment to support its clinical program for multiple Phase IB studies and the development of the product pipeline. At the completion of Phase IB studies the company expects to be in a strong position to licensing the technology. ORIL also recognizes the need to be flexible and ready for negotiation at any time, should a partnering opportunity arise.
ORIL considers that the risks can be mitigated by good management of the science and R&D program entailing the knowledge and experience of the key personnel, and that the milestones are deliverable and achievable based on results achieved to date, and that the timings are reasonable subject to necessary funding.
Registered Office
Oncology Research International Limited
Level 5, 45 St George Terrace,
Perth WA 6000 Australia